DDrare: Database of Drug Development for Rare Diseases

68ga-fapi (DrugBank: -)

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
46	悪性関節リウマチ	1
300	IgG4関連疾患	1

46. 悪性関節リウマチ　［臨床試験数：4,183，薬物数：2,538（DrugBank：401），標的遺伝子数：183，標的パスウェイ数：219］

Searched query = "Malignant rheumatoid arthritis", "Rheumatoid arthritis", "Rheumatoid arthritis with vasculitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 4,183 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04514614 (ClinicalTrials.gov)	October 1, 2020	7/8/2020	Characterizing Rheumatoid Arthritis With 68Ga-FAPI PET/CT	Characterizing Rheumatoid Arthritis With 68Ga-FAPI PET/CT	Arthritis	Drug: 68Ga-FAPI	Peking Union Medical College Hospital	NULL	Not yet recruiting	18 Years	90 Years	All	100	Early Phase 1	China

300. IgG4関連疾患　［臨床試験数：31，薬物数：33（DrugBank：16），標的遺伝子数：11，標的パスウェイ数：81］

Searched query = "IgG4-related disease", "Autoimmune pancreatitis", "IgG4-related sclerosing cholangitis", "IgG4-related lacrimal gland, orbital, and salivary gland lesions", "IgG4-related kidney disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 31 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04125511 (ClinicalTrials.gov)	November 1, 2019	28/8/2019	Characterizing IgG4-RD With 68Ga-FAPI PET/CT	Characterizing IgG4-related Disease With 68Ga-FAPI PET/CT	IgG4-related Disease	Drug: 68Ga-FAPI	Peking Union Medical College Hospital	NULL	Recruiting	18 Years	90 Years	All	100	Early Phase 1	China